Topic: acute ischemic stroke
The week’s biotech discoveries included eight mutations that contribute to cardiomyopathy and an enzyme that promotes basal-like breast cancer.
The offering gives DiaMedica the cash to take its lead candidate through phase 2 trials in acute ischemic stroke and chronic kidney disease.
Biogen signed an option deal worth up to $357 million for TMS’ stroke treatment currently being tested in a placebo-controlled phase 2 study in Japan.
The funding positions Silk Road to build on approvals and reimbursement nods it has picked up on both sides of the Atlantic for its TCAR devices.
The device senses the composition of blood clots to provide doctors with insights into how best to treat blockages.
Biogen has paid $120 million upfront for Remedy Pharmaceuticals’ phase 3 stroke asset Cirara.
The United Kingdom is making mechanical thrombectomy more widely available for patients who have suffered strokes.
MedyMatch inked a deal to integrate its decision-support technology with Samsung’s medical imaging machines in prehospital settings.
Medtronic’s Solitaire stent retriever has notched another indication, this time for the reduction of stroke-related disability in some patients suffering from acute ischemic stroke.
Kaiser Permanente’s telestroke program was first implemented in southern California medical centers between August 2013 and December 2014. Since then the program has proven itself by way of an increase in use of a lifesaving clot-dissolving treatment.